What Is Fecal Microbiota Transplant?

Fecal microbiota transplant (FMT) involves transferring stool from a healthy, carefully screened donor into the gastrointestinal tract of a patient with a disrupted microbiome. The goal is to restore a diverse, functional microbial ecosystem that the patient's own gut can no longer maintain. While the concept may seem unusual, FMT is one of the most dramatically effective treatments in modern medicine for its primary indication: recurrent Clostridioides difficile (C. diff) infection.

FMT can be delivered via colonoscopy, nasogastric tube, enema, or oral capsules containing processed donor stool. The FDA has approved two standardised FMT products for recurrent C. diff: Rebyota (a rectally administered product) and Vowst (an oral capsule formulation), marking a new era of microbiome-based therapeutics.

Established Indication: Recurrent C. difficile Infection

C. difficile infection causes severe diarrhoea, colonic inflammation, and in serious cases, toxic megacolon and death. Standard antibiotic treatment (vancomycin or fidaxomicin) cures the acute infection but leaves the underlying microbiome disruption unaddressed. As a result, approximately 25% of patients experience recurrence after a first episode, and recurrence rates climb with each subsequent episode.

FMT for recurrent C. diff has a cure rate of 85-90% after a single treatment, making it one of the most effective therapies in gastroenterology. Multiple randomised controlled trials have confirmed its superiority over repeated antibiotic courses. The mechanism is straightforward: the donor microbiome re-establishes competitive exclusion and colonisation resistance, preventing C. diff from re-establishing itself.

FMT for recurrent C. diff is now considered standard of care after two or more recurrences of C. diff infection that have failed standard antibiotic therapy. It is endorsed by the American Gastroenterological Association, the Infectious Diseases Society of America, and the European Society of Clinical Microbiology.

Conditions Under Investigation

Researchers are actively investigating FMT for numerous conditions beyond C. diff. The evidence ranges from promising to preliminary:

Inflammatory Bowel Disease

FMT for ulcerative colitis has shown the most promise among IBD subtypes. Four randomised controlled trials have been completed, with pooled remission rates of approximately 28% (compared to 9% for placebo). While this is modest compared to C. diff cure rates, it suggests that microbiome restoration can modulate the inflammatory process in UC. Results for Crohn's disease are less consistent, and further trials are ongoing.

IBS

Several RCTs have investigated FMT for IBS with mixed results. Some studies show significant symptom improvement (particularly for IBS-D), while others show no benefit or even worsening. The inconsistency likely reflects the heterogeneity of IBS and the difficulty in selecting optimal donors. Current evidence does not support routine FMT for IBS outside of clinical trials.

Metabolic Conditions

FMT from lean donors into patients with metabolic syndrome has shown transient improvements in insulin sensitivity and bile acid profiles in small studies. However, the metabolic benefits tend to wane over time, suggesting that without concurrent dietary and lifestyle changes, the transplanted microbiome reverts toward the recipient's pre-FMT state.

Neurological and Psychiatric Conditions

Pilot studies and case reports have explored FMT for autism spectrum disorder, Parkinson's disease, and major depression. While some results are intriguing, this research is at a very early stage and no neurological or psychiatric condition has sufficient evidence to recommend FMT outside of well-designed clinical trials.

Donor Screening and Safety

The safety of FMT depends heavily on rigorous donor screening. Reputable stool banks screen donors for:

  • Infectious diseases (HIV, hepatitis B and C, syphilis, C. diff, multi-drug resistant organisms, parasites)
  • Metabolic conditions, autoimmune diseases, and obesity
  • Recent antibiotic use, travel to high-risk areas, and high-risk behaviours
  • Detailed health questionnaires and regular follow-up screening

Serious adverse events from properly screened FMT are rare but have been reported, including transmission of drug-resistant bacteria and, in very rare cases, bacteraemia in immunocompromised recipients.

The Future of Microbiome Therapeutics

FMT represents the first generation of microbiome-based therapeutics. The field is rapidly evolving toward more refined approaches:

  • Defined consortia — specific combinations of bacterial strains selected for their functional capabilities, rather than whole stool
  • Engineered bacteria — genetically modified organisms designed to produce specific therapeutic molecules in the gut
  • Phage therapy — bacteriophages that selectively eliminate pathogenic species without disrupting the broader microbiome
  • Postbiotics — bacterial metabolites administered directly, bypassing the need for live organisms

While FMT for conditions beyond C. diff remains largely investigational, GutIQ can help you understand your current microbiome health status and whether you might benefit from discussing microbiome-targeted therapies with your gastroenterologist.